When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
YCCI’s third annual All-Scholar Day Retreat is slated for Tuesday, April 1, at the Anlyan Center. This half-day event is open to all students, trainees, Scholars and faculty at Yale who are participating or interested in clinical or translational research.
The event begins at noon with a poster session and lunch in the foyer of TAC. This year, YCCI welcomes speaker Christopher P. Austin, M.D., director of the National Center for Advancing Translational Sciences (NCATS). He will be joined by Richard Flavell, Ph.D., FRS, founding chair of the Department of Immunobiology. There will be an oral presentation of two abstracts in addition to our speakers.
Prior to his present appointment in 2012, Austin served as director of the NCATS Division of Pre-Clinical Innovation (DPI). He is leading NCATS in its mission to generate innovative methods and technologies to enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of diseases and conditions. Austin came to NIH in 2002 from Merck, where his work focused on genome-based discovery of novel targets and drugs. He began his NIH career as the senior advisor to the director for translational research at the National Human Genome Research Institute (NHGRI). He has also served as director of the Therapeutics for Rare and Neglected Disease program and the NIH Chemical Genomics Center, and as scientific director of the NIH Center for Translational Therapeutics.
Ricgard Flavell, PhD, FRS
Richard Flavell is Sterling Professor of Immunobiology and an Investigator of the Howard Hughes Medical Institute. His research uses mouse genetics to study innate and adaptive immunity, T cell tolerance, apoptosis and autoimmunity, and the regulation of T cell differentiation. Among his recent discoveries is the finding that genes interact across chromosomes in T cells, where a master control gene on mouse chromosome 11 may physically touch a gene on chromosome 10, inducing it to produce a protein that primes the cell to fight infection in a specific way. This finding has wide-ranging implications for human diseases that include autoimmune disorders and cancer. Most recently, Flavell has established the connection between inflammasomes, microbial homeostasis, and chronic diseases.